dc.contributor.author | Yigenoğlu, Tuğçe Nur | |
dc.contributor.author | Başçı, Semih | |
dc.contributor.author | Şahin, Derya | |
dc.contributor.author | Ulaş, Turgay | |
dc.contributor.author | Dal, Mehmet Sinan | |
dc.contributor.author | Korkmaz, Serdal | |
dc.contributor.author | Altuntaş, Fevzi | |
dc.contributor.author | Turgut, Burhan | |
dc.date.accessioned | 2022-05-11T14:40:01Z | |
dc.date.available | 2022-05-11T14:40:01Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 1473-0502 | |
dc.identifier.issn | 1878-1683 | |
dc.identifier.uri | https://doi.org/10.1016/j.transci.2021.103237 | |
dc.identifier.uri | https://hdl.handle.net/20.500.11776/8836 | |
dc.description.abstract | SARS-CoV-2 attaches to the angiotensin-converting enzyme 2 (ACE-2) receptor on human cells. The virus causes hypercytokinemia, capillary leak, pulmonary edema, acute respiratory distress syndrome, acute cardiac injury, and leads to death. Mesenchymal stem cells (MSCs) are ACE-2 negative cells; therefore, can escape from SARSCoV-2. MSCs prevent hypercytokinemia and help the resolution of the pulmonary edema and other damages occurred during the course of COVID-19. In addition, MSCs enhance the regeneration of the lung and other tissues affected by SARS-CoV-2. The case series reported beneficial effect of MSCs in COVID-19 treatment. However, there are some concerns about the safety of MSCs, particularly referring to the increased risk of disseminated intravascular coagulation, and thromboembolism due to the expression of TF/CD142. Prospective, randomized, large scale studies are needed to reveal the optimum dose, administration way, time, efficacy, and safety of MSCs in the COVID-19 treatment. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Pergamon-Elsevier Science Ltd | en_US |
dc.identifier.doi | 10.1016/j.transci.2021.103237 | |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Mesenchymal stem cell | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | Transfusion | en_US |
dc.subject | Transplantation | en_US |
dc.subject | Stromal Cells | en_US |
dc.subject | Tissue Factor | en_US |
dc.subject | Hla-G | en_US |
dc.subject | Therapy | en_US |
dc.subject | Transplantation | en_US |
dc.subject | Ace2 | en_US |
dc.title | Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients | en_US |
dc.type | review | en_US |
dc.relation.ispartof | Transfusion and Apheresis Science | en_US |
dc.department | Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0003-4304-9245 | |
dc.authorid | 0000-0002-3285-417X | |
dc.identifier.volume | 60 | en_US |
dc.identifier.issue | 6 | en_US |
dc.institutionauthor | Turgut, Burhan | |
dc.relation.publicationcategory | Diğer | en_US |
dc.authorscopusid | 57189243089 | |
dc.authorscopusid | 56545735000 | |
dc.authorscopusid | 57212584643 | |
dc.authorscopusid | 36456321300 | |
dc.authorscopusid | 56370690600 | |
dc.authorscopusid | 14022986200 | |
dc.authorscopusid | 37115534400 | |
dc.authorwosid | Başcı, Semih/AAB-4823-2021 | |
dc.authorwosid | Erkurt, Mehmet Ali/ABI-7232-2020 | |
dc.identifier.wos | WOS:000733239700018 | en_US |
dc.identifier.scopus | 2-s2.0-85113813802 | en_US |
dc.identifier.pmid | 34419356 | en_US |